Bio-Techne Corporation TECH

$ 72.4 0.32%

Quarterly report 2026-Q3
added 05-06-2026

Bio-Techne Corporation Income Statement 2025-2008 | TECH

Brief overview of revenue and earnings at Bio-Techne Corporation

The comparison covers a five-year financial horizon. According to figures from Bio-Techne Corporation, revenue changed from $739 million to $1.2 billion over five years. Overall revenue changed by +65.1%, equal to an annualized rate of about 10.5%. The trajectory reflects meaningful expansion of the business.

The five-year change in gross profit reached +63.6%: from 483 million dollars to 790 million dollars. The relationship between revenue and direct costs remained stable. Comparing the endpoints gives gross margins of 65.4% and 64.8%. There was no meaningful shift in gross profitability.

Over the period, EBITDA shifted from 240 million dollars to 212 million dollars, a change of −11.7%. Operating performance weakened relative to revenue. EBITDA margin moved from 32.5% to 17.4%. The business retained less EBITDA from each unit of revenue.

The net result moved from $229 million to $73.4 million, or −68%. The decline reduces the quality of the financial trajectory.

The market value of the business moved from 12.4 billion dollars to 9 billion dollars, or −27.3%. The negative valuation trend points to increased investor caution.

Summary assessment

The indicators point to a weaker financial profile. The constructive conclusion rests on sales growth and a stable gross margin. The overall view is constrained by declining net profitability, a declining EBITDA margin and a weaker market valuation. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.

Annual Income Statement Bio-Techne Corporation

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
Market Cap	8.99 B	11.3 B	12.4 B	60.1 B	58.3 B	12.4 B	7.95 B	5.9 B	4.35 B	4.18 B	4.08 B	3.46 B	2.71 B	2.69 B	2.81 B	559 M	578 M	-
Shares	158 M	158 M	157 M	157 M	155 M	38.2 M	37.8 M	37.5 M	37.3 M	37.2 M	37.1 M	36.9 M	36.8 M	36.9 M	37.1 M	37.3 M	37.8 M	-
Historical Prices	57.1	71.3	78.7	383	376	324	208	172	137	98.2	78.7	87.4	84.2	65.3	61.1	15	15.3	19
Net Income	73.4 M	168 M	285 M	272 M	140 M	229 M	96.1 M	126 M	76.1 M	104 M	108 M	111 M	113 M	112 M	112 M	110 M	105 M	-
Revenue	1.22 B	1.16 B	1.14 B	1.11 B	931 M	739 M	714 M	643 M	563 M	499 M	452 M	358 M	311 M	315 M	290 M	-	-	-
Cost of Revenue	429 M	389 M	367 M	349 M	298 M	255 M	241 M	211 M	188 M	162 M	145 M	106 M	79.5 M	78.8 M	65 M	54.9 M	55.9 M	-
Gross Profit	790 M	770 M	770 M	756 M	633 M	483 M	473 M	432 M	375 M	337 M	307 M	251 M	231 M	236 M	225 M	214 M	208 M	-
Operating Income	102 M	207 M	299 M	297 M	237 M	157 M	147 M	136 M	121 M	151 M	147 M	160 M	158 K	166 M	163 M	156 M	151 M	-
Interest Expense	831 K	-8.58 M	11.2 M	11.3 M	14 M	19.2 M	21.7 M	10.2 M	7.36 M	1.75 M	1.54 M	-	-	-3.4 M	-1.83 M	-4.26 M	-3.05 M	-
EBITDA	212 M	318 M	406 M	398 M	325 M	240 M	172 M	199 M	166 M	193 M	184 M	177 M	169 M	177 M	172 M	164 M	159 M	-
Operating Expenses	688 M	563 M	471 M	460 M	396 M	326 M	326 M	298 M	230 M	186 M	160 M	93.6 M	74.8 M	71.7 M	61.9 M	57.8 M	57.3 M	-
General and Administrative Expenses	589 M	466 M	378 M	373 M	325 M	261 M	237 M	241 M	153 M	141 M	119 M	60.7 M	43.4 M	41.7 M	35.9 M	32.7 M	33.7 M	-

All numbers in USD currency

Quarterly Income Statement Bio-Techne Corporation

	2026-Q3	2026-Q2	2026-Q1	2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Shares	156 M	156 M	155 M	156 M	155 M	155 M	157 M	158 M	159 M	158 M	157 M	158 M	158 M	158 M	157 M	157 M	157 M	157 M	157 M	157 M	39.1 M	157 M	38.9 M	38.7 M	38.5 M	38.7 M	38.5 M	38.2 M	38 M	38.2 M	38 M	37.8 M	37.7 M	37.8 M	37.7 M	37.4 M	37.4 M	37.4 M	37.4 M	37.3 M	37.3 M	37.3 M	37.3 M	37.2 M	37.2 M	37.2 M	37.2 M	37.1 M	37 M	37.1 M	37 M	36.9 M	36.8 M	36.9 M	36.8 M	36.8 M	36.8 M	36.8 M	36.8 M	37 M	37.1 M	37 M	37.1 M
Net Income	51 M	38 M	38.2 M	38 M	38.2 M	-	22.6 M	34.9 M	33.6 M	-	49.1 M	27.5 M	51 M	-	70.2 M	50 M	89.6 M	140 M	60.7 M	72.1 M	69 M	150 M	45.8 M	46.3 M	33.4 M	46.3 M	33.4 M	120 M	120 M	120 M	14.4 M	17.6 M	17.6 M	17.6 M	17.4 M	48.8 M	15.9 M	48.8 M	15.9 M	7.47 M	18.8 M	6.31 M	16.3 M	25.9 M	22.7 M	25.9 M	22.7 M	33.2 M	23.9 M	33.2 M	23.9 M	25.1 M	27.4 M	25.1 M	27.4 M	25.4 M	25.7 M	25.4 M	25.7 M	25.8 M	27.5 M	25.8 M	27.5 M
Revenue	311 M	296 M	287 M	296 M	287 M	-	316 M	297 M	289 M	-	303 M	273 M	277 M	-	294 M	272 M	270 M	541 M	290 M	269 M	258 M	527 M	244 M	224 M	204 M	224 M	204 M	185 M	183 M	185 M	183 M	175 M	163 M	175 M	163 M	154 M	145 M	299 M	144 M	132 M	131 M	132 M	131 M	121 M	112 M	121 M	112 M	112 M	108 M	112 M	108 M	84 M	85.7 M	84 M	85.7 M	75.1 M	75 M	75.1 M	75 M	74.7 M	77.6 M	74.7 M	77.6 M
Cost of Revenue	103 M	105 M	98.4 M	105 M	98.4 M	-	102 M	103 M	106 M	-	98.8 M	96 M	91.7 M	-	92 M	88.2 M	90.1 M	178 M	88.9 M	85.6 M	86.7 M	172 M	75.3 M	73.4 M	66.5 M	73.4 M	66.5 M	63.5 M	64.8 M	63.5 M	64.8 M	61.5 M	55.4 M	61.5 M	55.4 M	52.3 M	46.7 M	52.3 M	46.7 M	43.7 M	43.2 M	46.7 M	46.1 M	39.3 M	37 M	39.3 M	37 M	36.2 M	35.4 M	36.2 M	35.4 M	25.4 M	24.6 M	25.4 M	24.6 M	19.8 M	19.4 M	19.8 M	19.4 M	19.5 M	19.2 M	19.5 M	19.2 M
Gross Profit	208 M	191 M	188 M	191 M	188 M	-	215 M	194 M	183 M	-	205 M	177 M	185 M	-	202 M	183 M	180 M	363 M	201 M	184 M	171 M	355 M	168 M	151 M	138 M	151 M	138 M	121 M	118 M	121 M	118 M	113 M	108 M	113 M	108 M	102 M	97.9 M	102 M	97.9 M	88.1 M	87.3 M	85.1 M	84.5 M	81.6 M	75.4 M	81.6 M	75.4 M	75.7 M	73.1 M	75.7 M	73.1 M	58.6 M	61.1 M	58.6 M	61.1 M	55.3 M	55.6 M	55.3 M	55.6 M	55.2 M	58.4 M	55.2 M	58.4 M
Operating Income	75.5 M	54.5 M	47.7 M	54.5 M	47.7 M	-	38.7 M	47.4 M	40 M	-	67 M	38 M	55.9 M	-	80.2 M	67.9 M	56.3 M	124 M	90.4 M	62.3 M	63.2 M	126 M	68.6 M	51 M	49.1 M	51 M	49.1 M	37 M	33.3 M	37 M	33.3 M	33.6 M	25.8 M	33.6 M	25.8 M	24.1 M	26 M	24.1 M	26 M	17.9 M	29.2 M	16.1 M	25.4 M	36 M	31 M	36 M	31 M	34.6 M	35.2 M	34.6 M	35.2 M	35.7 M	39.4 M	35.7 M	39.4 M	36.9 M	37.8 M	36.9 M	37.8 M	37.7 M	40.9 M	37.7 M	40.9 M
Interest Expense	-	-	-	-	-	-	-	-	-	-	4 M	4.33 M	4.89 M	-	1.37 M	2.36 M	3.79 M	6.15 M	2.49 M	2.9 M	3.41 M	6.31 M	2.66 M	3.58 M	4.42 M	3.58 M	4.42 M	4.87 M	5.22 M	4.87 M	5.22 M	5.76 M	5.24 M	5.76 M	5.24 M	2.33 M	2.24 M	2.33 M	2.24 M	1.92 M	1.4 M	1.84 M	1.34 M	400 K	451 K	400 K	451 K	437 K	311 K	437 K	311 K	-	-	-71 K	-304 K	-135 K	-478 K	-135 K	-478 K	-607 K	-1.18 M	-607 K	-1.18 M
EBITDA	149 M	104 M	72 M	70 M	72 M	-	-	66.3 M	68.1 M	-	-	-	84.4 M	-	-	67.9 M	83 M	178 M	146 M	99.6 M	88 M	175 M	68.6 M	51 M	70.2 M	93 M	70.2 M	37 M	53.4 M	77.6 M	33.3 M	33.6 M	44.8 M	72.5 M	44.8 M	24.1 M	41.5 M	55.2 M	41.5 M	17.9 M	42.8 M	45.4 M	25.4 M	43.4 M	41.7 M	57.3 M	41.7 M	41.4 M	43.8 M	53 M	43.8 M	38.3 M	43.5 M	44.7 M	43.5 M	36.9 M	40.9 M	43.2 M	40.9 M	37.7 M	44.1 M	44 M	44.1 M
Operating Expenses	133 M	137 M	140 M	137 M	140 M	-	176 M	146 M	143 M	-	138 M	139 M	129 M	-	122 M	115 M	123 M	239 M	111 M	121 M	108 M	229 M	99.6 M	99.9 M	88.6 M	99.9 M	88.6 M	84.4 M	85.1 M	84.4 M	85.1 M	79.4 M	81.8 M	79.4 M	81.8 M	77.7 M	71.8 M	77.7 M	71.8 M	70.3 M	58.2 M	68.9 M	59 M	45.6 M	44.4 M	45.6 M	44.4 M	41.2 M	37.8 M	41.2 M	37.8 M	22.8 M	21.7 M	22.8 M	21.7 M	18.4 M	17.8 M	18.4 M	17.8 M	17.5 M	17.4 M	17.5 M	17.4 M
General and Administrative Expenses	109 M	114 M	116 M	114 M	116 M	-	151 M	121 M	119 M	-	112 M	116 M	105 M	-	99.2 M	93 M	99.4 M	192 M	89.3 M	101 M	86.2 M	187 M	82.6 M	83.1 M	72.6 M	83.1 M	72.6 M	68 M	69 M	68 M	69 M	63.6 M	67.1 M	63.6 M	67.1 M	63.8 M	58.3 M	63.8 M	58.3 M	57 M	45.4 M	55.7 M	46.3 M	34.6 M	33 M	34.6 M	33 M	31.1 M	28.7 M	31.1 M	28.7 M	14.9 M	14 M	14.9 M	14 M	11 M	10.3 M	11 M	10.3 M	10.7 M	10.8 M	10.7 M	10.8 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Bio-Techne Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

How much revenue the company earned
How much it spent on production, personnel, marketing, taxes, etc.
What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features

The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer	Price	% 24h	Market Cap	Country
Celsion Corporation CLSN	-	-6.63 %	$ 13.9 M	USA
FSD Pharma HUGE	-	5743.5 %	$ 69.7 M	Canada
Qilian International Holding Group Limited QLI	-	-6.08 %	$ 184 M	China
Happiness Biotech Group Limited HAPP	-	1.35 %	$ 17.8 M	China
Synthetic Biologics SYN	-	1.32 %	$ 16.2 M	USA
Dynavax Technologies Corporation DVAX	-	-	$ 2.02 B	USA
BioXcel Therapeutics BTAI	$ 1.19	5.31 %	$ 14.5 M	USA
Burford Capital Limited BUR	$ 4.37	0.23 %	$ 958 M	Britain
I-Mab IMAB	-	-	$ 866 M	China
BeyondSpring BYSI	$ 0.84	34.27 %	$ 34.5 M	USA
Corner Growth Acquisition Corp. COOL	-	-0.89 %	$ 114 M	USA
AgeX Therapeutics AGE	-	-10.17 %	$ 12.2 K	USA
Alexion Pharmaceuticals, Inc. ALXN	-	-	$ 40.3 B	USA
Genfit SA GNFT	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	-	-13.47 %	$ 169 M	France
Cerus Corporation CERS	$ 2.98	4.93 %	$ 568 M	USA
Compugen Ltd. CGEN	$ 2.41	4.17 %	$ 225 M	Israel
CureVac N.V. CVAC	-	-	$ 867 M	Germany
EyeGate Pharmaceuticals, Inc. EYEG	-	-1.52 %	$ 24.7 M	USA
Athira Pharma ATHA	-	-	$ 269 M	USA
BiondVax Pharmaceuticals Ltd. BVXV	-	0.74 %	$ 768 M	Israel
Abcam plc ABCM	-	-	$ 4.9 B	Britain
Завод ДИОД DIOD	-	-	-	Russia
Galera Therapeutics GRTX	-	-32.59 %	$ 7.61 M	USA
Midatech Pharma plc MTP	-	-18.52 %	$ 27.3 M	Britain
Hepion Pharmaceuticals HEPA	-	-18.79 %	$ 39.3 K	USA
ARCA biopharma ABIO	-	1052.0 %	$ 415 M	USA
MorphoSys AG MOR	-	2.43 %	$ 254 M	Germany
Champions Oncology CSBR	$ 5.1	2.63 %	$ 70.5 M	USA
Affimed N.V. AFMD	-	-34.95 %	$ 21.5 M	Germany
AnPac Bio-Medical Science Co., Ltd. ANPC	-	-1.58 %	$ 28.1 M	China
Celyad Oncology SA CYAD	-	-	$ 12.5 M	Belgium
Adial Pharmaceuticals ADIL	$ 3.98	1.86 %	$ 2.66 M	USA
Generation Bio Co. GBIO	-	-	$ 344 M	USA
Akero Therapeutics AKRO	-	-	$ 3.67 B	USA
AnaptysBio ANAB	$ 58.47	4.37 %	$ 1.68 B	USA
Anika Therapeutics ANIK	$ 21.5	1.56 %	$ 308 M	USA
Cyclacel Pharmaceuticals CYCCP	-	-4.36 %	$ 27 M	USA
Gracell Biotechnologies GRCL	-	-	$ 3.37 B	China
Aurinia Pharmaceuticals AUPH	$ 15.47	1.91 %	$ 2.08 B	Canada
GlycoMimetics GLYC	-	9357.83 %	$ 1.01 B	USA
Aeterna Zentaris AEZS	-	5.93 %	$ 314 M	Canada
AVROBIO AVRO	-	1083.1 %	$ 745 M	USA
BeiGene, Ltd. BGNE	-	0.49 %	$ 251 B	Cayman-islands
Bicycle Therapeutics plc BCYC	$ 3.9	0.24 %	$ 270 M	Britain
Beam Therapeutics BEAM	$ 26.75	0.91 %	$ 2.65 B	USA
AIkido Pharma AIKI	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	-	-	$ 1.01 B	USA
BioMarin Pharmaceutical BMRN	$ 67.36	0.99 %	$ 12.9 B	USA
Aptose Biosciences APTO	-	-45.71 %	$ 1.2 M	Canada

Bio-Techne Corporation Income Statement 2025-2008 | TECH

Brief overview of revenue and earnings at Bio-Techne Corporation

Summary assessment

Annual Income Statement Bio-Techne Corporation

Market Cap

Shares

Historical Prices

Net Income

Revenue

Cost of Revenue

Gross Profit

Operating Income

Interest Expense

EBITDA

Operating Expenses

General and Administrative Expenses